Portolan Capital Management LLC Has $5.07 Million Stake in MaxCyte, Inc. (NASDAQ:MXCT)

Portolan Capital Management LLC trimmed its position in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 22.8% in the third quarter, Holdings Channel reports. The fund owned 1,303,438 shares of the company’s stock after selling 384,212 shares during the quarter. Portolan Capital Management LLC’s holdings in MaxCyte were worth $5,070,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in MaxCyte in the 3rd quarter valued at approximately $51,000. China Universal Asset Management Co. Ltd. boosted its position in shares of MaxCyte by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after acquiring an additional 7,930 shares during the period. Verition Fund Management LLC increased its position in MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after acquiring an additional 6,045 shares during the period. Price T Rowe Associates Inc. MD raised its stake in MaxCyte by 20.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock valued at $106,000 after purchasing an additional 4,320 shares during the last quarter. Finally, Creative Planning boosted its holdings in MaxCyte by 33.6% in the 3rd quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after purchasing an additional 7,212 shares during the period. 68.81% of the stock is currently owned by institutional investors.

Insider Transactions at MaxCyte

In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the sale, the director now directly owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. The trade was a 7.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 27,607 shares of company stock valued at $102,782. Company insiders own 3.00% of the company’s stock.

MaxCyte Stock Performance

NASDAQ MXCT opened at $3.58 on Wednesday. MaxCyte, Inc. has a twelve month low of $3.16 and a twelve month high of $5.55. The stock has a market cap of $377.62 million, a PE ratio of -10.53 and a beta of 1.37. The firm has a 50-day simple moving average of $3.65 and a 200 day simple moving average of $4.09.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $8.16 million for the quarter, compared to analysts’ expectations of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same period in the previous year, the business posted ($0.11) earnings per share. Research analysts forecast that MaxCyte, Inc. will post -0.43 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.